Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Drug Discovery Today. Technologies|November 1, 2013
Fixing clearance as early as lead optimization using high throughput in vitro incubations in combination with exact mass detection and automatic structure elucidation of metabolitesAlfred Zimmerlin, Michael KiffeDrug Metabolism and Disposition: the Biological Fate of Chemicals|March 9, 2011
CYP3A time-dependent inhibition risk assessment validated with 400 reference drugsAlfred Zimmerlin, Markus Trunzer, Bernard FallerJournal of Medicinal Chemistry|December 26, 2008
Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validationMarkus Trunzer, Bernard Faller, Alfred ZimmerlinChemical Research in Toxicology|June 12, 2020
New Perspectives on Drug-Induced Liver Injury Risk Assessment of Acyl GlucuronidesMarkus Walles, Alan P Brown, Alfred Zimmerlin, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 4, 2010
CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosisYi Jin, Markus Zollinger, Hubert Borell, et al.Expert Opinion on Drug Metabolism & Toxicology|November 28, 2006
High-throughput in vitro profiling assays: lessons learnt from experiences at NovartisBernard Faller, Jianling Wang, Alfred Zimmerlin, et al.Journal of Biomolecular Screening|May 14, 2008
Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discoveryLeslie Bell, Shari Bickford, Phong Hung Nguyen, et al.ACS Medicinal Chemistry Letters|October 18, 2019
Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive ConformationRobert Pulz, Daniela Angst, Janet Dawson, et al.Journal of Medicinal Chemistry|February 22, 2020
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine KinaseDaniela Angst, François Gessier, Philipp Janser, et al.Journal of Medicinal Chemistry|September 23, 2011
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinaseVito Guagnano, Pascal Furet, Carsten Spanka, et al.Pageof 2